KRAS and acute lymphoblastic leukemia: Based on 261 (25.9%) of the non-silent mutations predicted to be deleterious, we estimated the mutation prevalence and found that recurrently mutated genes with a mutation prevalence over 5% included KRAS (8.76%), NRAS (6.4%), FLT3 (5.7%) and KMT2D (5.0%) in childhood ALL.